MedWaves, a developer of microwave ablation technology, has received the receipt of the Chinese State Food and Drug Administration (SFDA) approval to import and sell its patented AveCure microwave coagulation-ablation (MWA) system.
AveCure MWA system utilizes microwave energy and aids clinicians with patented real-time temperature, both forward and reverse-power feedback to control energy delivery.
The system consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices facilitating surgeons and interventional radiologists to ablate soft-tissue lesions, such as tumors.
The company informed that it will work in coordination with its Chinese distributor-partners to conduct and schedule clinical evaluations for the sale of its AveCure system in hospitals in China.
The company plans to bring its technology to treat lesions in other locations in the body.
MedWaves has also received USFDA approval to commercialize AveCure MWA System in the US and CE mark for sales in Europe.